Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Norway / NCT03685006
Active, not recruiting Observational

Atherosclerosis and Acute Ischemic Stroke Study

NCT03685006 · tracked via the Priya Life Science Norway tracker
Sponsor
Oslo University Hospital
Phase
Observational
Started
2009-01-01
Last updated
2022-04-25

Condition(s) studied

AtherosclerosisInflammationIschemic Stroke

Study summary

A significant proportion of strokes are thromboembolic in nature, arising from atherosclerotic plaque at the carotid bifurcation. It is now wellknown that inflammation plays a key role in atherogenesis and plaque destabilization. However the identification and characterization of the different inflammatory factors, as well as their relative importance, have not been clarified. This main aim of this study is to identify new risk markers for atherosclerosis and to characterize more precise methods for detection of the unstable carotid plaque with increased stroke-risk.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * All patients with an atherosclerotic carotid stenosis \>50% admitting one of the study centres as an in-patient or an out-patient will be considered for inclusion. * Acute stroke patients treated with thrombectomy at Oslo University Hospital will be included even though the carotid stenosis is \< 50%. Exclusion Criteria: * Malign disease * Inflammatory disease

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Oslo University Hospital Oslo Norway

More Oslo University Hospital trials in Norway

Cervical Radiculopathy Trial Active, not recruiting
Nutrition Therapy in the Immature Infant (ImNuT) Active, not recruiting
The HIP Self-management Study Active, not recruiting
Novel Technologies to Improve Echocardiographic Estimates of Left Ventricular Filling Pressure in Heart Failure Combined With Atrial Fibrillation Recruiting
Natural History Study of Retinitis Pigmentosa Type 11 Active, not recruiting

Other trials for the same condition

Improving Stroke Care in North-Norway Through Artificial Intelligence Recruiting
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants Recruiting
A Population-based Investigation of Asthma in the Telemark Region of Norway Active, not recruiting
The Gut and Oral Bacteria, Atherosclerosis and Ischemic Stroke Study Active, not recruiting
Profiling Vulnerability and Resilience for Mental Illness Following Viral Infections Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03685006 on ClinicalTrials.gov ↗ ← All trials in Norway